M1-c6v1

AXP000129.1 · Oncolytic virus

Platform
oncolytic alphavirus M1 (engineered variant)
Originator
Sun Yat-sen University
Sponsor
Guangzhou Virotech Pharmaceutical

Names

NameTypeSource
M1-c6v1preferred name, codecurator, ctgov

Virus

Role
Oncolytic
Family
Togaviridae
Virus
Getah virus (NCBI Taxonomy 59300)
Strain
M1-c6v1
Replication
replicating
Modifications
engineered M1 alphavirus variant; details not disclosed
Route
intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06046742A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid TumorsRecruitingPhase 12024-07-102028-06-3012Solid Tumor
NCT04665362IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCCUnknownPhase 12021-01-252022-06-0110Advanced/Metastatic Hepatocellular Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40788183Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in title: M1-c6v1

Notes

Engineered M1 variant given intravenously (NCT06046742); entered separately from VRT106 because the two were taken into humans as different agents by the same sponsor. Whether they are genuinely different constructs needs checking with the sponsor.

How to cite

M1-c6v1 (AXP000129.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000129.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.